This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety ImmunogenicitySafety ProfileIn Your Practice In Your PracticeSimplified CombinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeHealth Plan CoverageMaterialsVideos
Prescribing InformationIndicationsPatient SiteRequest a RepLoading
PENBRAYA® may help simplify meningococcal vaccinationAs a combination vaccine, PENBRAYA may positively impact certain aspects of vaccination1,2For you and your office staff: For patients and caregivers: Both ACIP and AAP guidelines for immunization state that the use of combination vaccines is generally preferred over separate injections of the equivalent component vaccines.1,7,8Both ACIP and AAP guidelines for immunization state that the use of combination vaccines is generally preferred over separate injections of the equivalent component vaccines.1,7,8One less injection is needed for healthy adolescents at age 16 to complete the recommended meningococcal vaccination schedule compared to separate MenACWY and MenB vaccines.4Based on a recent survey of parents and caregivers of teens aged 15 to 18 years (n=1000).5AAP=American Academy of Pediatrics; ACIP=Advisory Committee on Immunization Practices.Quick links Dosing and Recommendations

Learn about ACIP-recommended dosing for PENBRAYA

 See dosing Loading How to Transition to PENBRAYA

See how Pfizer can help your practice transition to PENBRAYA 

 Find out how Loading Preparing PENBRAYA

See the benefits of the PENBRAYA Needle-Free† Reconstitution Kit

†Needle for administration is not included.

 Get started Loadingcircle icon of syringe representing dosing and recommendations Dosing and Recommendations

Learn about ACIP-recommended dosing for PENBRAYA

 See dosing Loadingcircle icon of a line symbol representing a practice transitioning to PENBRAYA (meningococcal groups A, B, C, W, and Y vaccine) How to Transition to PENBRAYA

See how Pfizer can help your practice transition to PENBRAYA 

 Find out how LoadingCircle icon of hand Preparing PENBRAYA

See the benefits of the PENBRAYA Needle-Free† Reconstitution Kit

†Needle for administration is not included.

 Get started Loading

References: 1. Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Centers for Disease Control and Prevention. Accessed January 13, 2025. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf 2. PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine). Prescribing information. Pfizer Inc.; 2024. 3. Bekkat-Berkani R, Fragapane E, Preiss S, et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85(5):481-491. 4. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 5. Data on file. Meningococcal HCP and Consumer Survey. Pfizer Inc., New York, NY. 6. Data on file. Meningococcal HCP and Consumer Survey. [suppl data]. Pfizer Inc., New York, NY. 7. American Academy of Pediatrics. Combination vaccines. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126(1):186-190. 8. Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Washington, DC: Public Health Foundation; 2021.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PBI-USA-0409
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age